Abbisko Therapeutics Co., Ltd. announced that two major clinical updates of its CSF-1R inhibitor pimicotinib (ABSK021) were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.
Abbisko Therapeutics Co., Ltd. announced that two major clinical updates of its CSF-1R inhibitor pimicotinib (ABSK021) were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held in Ireland from November 1 to 4, 2023.